Sunitinib and Axitinib in Renal Cell Carcinoma

摘要: Sunitinib and axitinib are two oral, small-molecule agents that emerged from the same drug discovery program. They were rationally designed for selective inhibition of receptor tyrosine kinases (RTK), critically involved in human tumor malignancies. Sunitinib, more extensively studied two, has demonstrated unprecedented antitumor activity phase II studies cytokine-refractory metastatic renal cell carcinoma (mRCC) statistically significant superiority over interferon-alfa as first-line therapy patients with mRCC. These data have established sunitinib a new reference standard care mRCC setting. Axitinib also setting, well shown encouraging results second-line patients, refractory to prior RTK inhibition. In this chapter, we will discuss each compound turn, briefly reviewing preclinical I development each, before summarizing clinical available date use mRCC, including biomarker both drugs discussion different patient populations, combination other targeted agents, at dosing schedules.